Skip to main content

Advertisement

SpringerLink
Log in

Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study

  • Original article
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

Abstract

Background

To compare the safety and efficacy of benzbromarone and febuxostat in hyperuricemia patients with estimated glomerular filtration rate (eGFR) 20–60 mL/min/1.73 m2.

Methods

This study was a single-centered, parallel-grouped, randomized clinical trial (RCT). We randomly assigned hyperuricemia participants with eGFR 20–60 mL/min/1.73 m2 into benzbromarone and febuxostat treatment group. Drugs were adjusted by titration from small doses.

Results

Seventy-three eligible participants enrolled, 66 subjects (33 in each group) were included finally for analysis. When compared to baseline, serum uric acid (SUA) decreased significantly after treatment in both groups, but no differences were detected among all the follow-up points. After 12-month treatment, eGFR did not have significant change in both groups. In the benzbromarone group, kidney stones in one case increased in quantity. In the febuxostat group, kidney stones in one case became smaller in size and in two cases vanished completely. Both drugs did not increase myocardial enzymes significantly after the treatment. In addition, hemoglobin increased significantly in the two groups (p < 0.05).

Conclusions

Benzbromarone and febuxostat could reduce SUA and maintain renal function in chronic kidney disease (CKD) patients with eGFR 20–60 mL/min/1.73 m2. Urate-lowering therapy with benzbromarone or febuxostat could increase serum hemoglobin level and potentially improve anemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Srivastava A, Kaze AD, McMullan CJ, Isakova T, Waikar SS. uric acid and the risks of kidney failure and death in individuals with CKD. Am J Kidney Dis. 2017. https://doi.org/10.1053/j.ajkd.2017.08.017.

    Article  PubMed  Google Scholar 

  2. Rincon-Choles H, Jolly SE, Arrigain S, Konig V, Schold JD, Nakhoul G, Navaneethan SD, Nally JV Jr, Rothberg MB. Impact of uric acid levels on kidney disease progression. Am J Nephrol. 2017;46(4):315–22. https://doi.org/10.1159/000481460.

    Article  CAS  PubMed  Google Scholar 

  3. Haga Y, Ohtsubo T, Murakami N, Noguchi H, Kansui Y, Goto K, Matsumura K, Kitazono T. Disruption of xanthine oxidoreductase gene attenuates renal ischemia reperfusion injury in mice. Life Sci. 2017;182:73–9. https://doi.org/10.1016/j.lfs.2017.06.011.

    Article  CAS  PubMed  Google Scholar 

  4. Scheepers LE, Wei FF, Stolarz-Skrzypek K, Malyutina S, Tikhonoff V, Thijs L, Salvi E, Barlassina C, Filipovsky J, Casiglia E, Nikitin Y, Kawecka-Jaszcz K, Manunta P, Cusi D, Boonen A, Staessen JA, Arts IC. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertens. 2016;34(11):2147–54. https://doi.org/10.1097/HJH.0000000000001077.

    Article  CAS  PubMed  Google Scholar 

  5. Pinheiro LC, Oliveira-Paula GH, Portella RL, Guimaraes DA, de Angelis CD, Tanus-Santos JE. Omeprazole impairs vascular redox biology and causes xanthine oxidoreductase-mediated endothelial dysfunction. Redox Biol. 2016;9:134–43. https://doi.org/10.1016/j.redox.2016.08.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Battelli MG, Polito L, Bolognesi A. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress. Atherosclerosis. 2014;237(2):562–7. https://doi.org/10.1016/j.atherosclerosis.2014.10.006.

    Article  CAS  PubMed  Google Scholar 

  7. Ohtsubo T, Matsumura K, Sakagami K, Fujii K, Tsuruya K, Noguchi H, Rovira II, Finkel T, Iida M. Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules. Hypertension. 2009;54(4):868–76. https://doi.org/10.1161/HYPERTENSIONAHA.109.135152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Tin A, Woodward OM, Kao WH, Liu CT, Lu X, Nalls MA, Shriner D, Semmo M, Akylbekova EL, Wyatt SB, Hwang SJ, Yang Q, Zonderman AB, Adeyemo AA, Palmer C, Meng Y, Reilly M, Shlipak MG, Siscovick D, Evans MK, Rotimi CN, Flessner MF, Kottgen M, Cupples LA, Fox CS, Kottgen A, Care, Consortia C. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. Hum Mol Genet. 2011;20(20):4056–68. https://doi.org/10.1093/hmg/ddr307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sorensen CM, Chandhoke PS. Hyperuricosuric calcium nephrolithiasis. Endocrinol Metab Clin N Am. 2002;31(4):915–25.

    Article  CAS  Google Scholar 

  10. Pak CY, Moe OW, Sakhaee K, Peterson RD, Poindexter JR. Physicochemical metabolic characteristics for calcium oxalate stone formation in patients with gouty diathesis. J Urol. 2005;173(5):1606–9.

    Article  CAS  Google Scholar 

  11. Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.

    Article  Google Scholar 

  12. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, Pillinger MH, Merill J, Lee S, Prakash S, Kaldas M, Gogia M, Perez-Ruiz F, Taylor W, Liote F, Choi H, Singh JA, Dalbeth N, Kaplan S, Niyyar V, Jones D, Yarows SA, Roessler B, Kerr G, King C, Levy G, Furst DE, Edwards NL, Mandell B, Schumacher HR, Robbins M, Wenger N, Terkeltaub R, American College of R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012; 64(10):1431–46. https://doi.org/10.1002/acr.21772.

    Article  CAS  Google Scholar 

  13. Johnson RJ, Bakris GL, Borghi C, Chonchol MB, Feldman D, Lanaspa MA, Merriman TR, Moe OW, Mount DB, Sanchez Lozada LG, Stahl E, Weiner DE, Chertow GM. Hyperuricemia, acute and chronic kidney disease, hypertension, and cardiovascular disease: report of a scientific workshop organized by the National Kidney Foundation. Am J Kidney Dis. 2018. https://doi.org/10.1053/j.ajkd.2017.12.009.

    Article  PubMed  Google Scholar 

  14. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16:58. https://doi.org/10.1186/s12882-015-0047-z.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bose B, Badve SV, Hiremath SS, Boudville N, Brown FG, Cass A, de Zoysa JR, Fassett RG, Faull R, Harris DC, Hawley CM, Kanellis J, Palmer SC, Perkovic V, Pascoe EM, Rangan GK, Walker RJ, Walters G, Johnson DW. Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2014;29(2):406–13. https://doi.org/10.1093/ndt/gft378.

    Article  CAS  PubMed  Google Scholar 

  16. Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskelet Disord. 2015;16(1):296.

    Article  Google Scholar 

  17. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553–62. https://doi.org/10.1681/ASN.2005050572.

    Article  CAS  PubMed  Google Scholar 

  18. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 2008;26(2):269–75. https://doi.org/10.1097/HJH.0b013e3282f240bf.

    Article  CAS  PubMed  Google Scholar 

  19. Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, Johnson RJ, Kang DH. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013;304(5):F471-480. https://doi.org/10.1152/ajprenal.00560.2012.

    Article  CAS  Google Scholar 

  20. Zhou Y, Fang L, Jiang L, Wen P, Cao H, He W, Dai C, Yang J. Uric acid induces renal inflammation via activating tubular NF-kappaB signaling pathway. PLoS One. 2012;7(6):e39738. https://doi.org/10.1371/journal.pone.0039738.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sugahara M, Tanaka T, Nangaku M. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney Int. 2017;92(2):306–12. https://doi.org/10.1016/j.kint.2017.02.035.

    Article  CAS  PubMed  Google Scholar 

  22. Fields M, Lewis CG, Lure MD. Allopurinol, an inhibitor of xanthine oxidase, reduces uric acid levels and modifies the signs associated with copper deficiency in rats fed fructose. Free Radic Biol Med. 1996;20(4):595–600.

    Article  CAS  Google Scholar 

  23. Liakopoulos V, Roumeliotis S, Gorny X, Dounousi E, Mertens PR. Oxidative stress in hemodialysis patients: a review of the literature. Oxid Med Cell Longev. 2017. https://doi.org/10.1155/2017/3081856.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Mehta TH, Goldfarb DS. Uric acid stones and hyperuricosuria. Adv Chronic Kidney Dis. 2012;19(6):413–8. https://doi.org/10.1053/j.ackd.2012.07.014.

    Article  PubMed  Google Scholar 

  25. Asplin JR. Uric acid stones. Semin Nephrol. 1996;16(5):412–24.

    CAS  PubMed  Google Scholar 

  26. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386–9. https://doi.org/10.1056/nejm198611273152204.

    Article  CAS  PubMed  Google Scholar 

  27. Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008;73(4):489–96. https://doi.org/10.1038/sj.ki.5002708.

    Article  CAS  PubMed  Google Scholar 

  28. Goldfarb DS. Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria. Clin J Am Soc Nephrol. 2011;6(8):2093–7. https://doi.org/10.2215/CJN.00320111.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Arowojolu O, Goldfarb DS. Treatment of calcium nephrolithiasis in the patient with hyperuricosuria. J Nephrol. 2014;27(6):601–5. https://doi.org/10.1007/s40620-014-0084-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200–10. https://doi.org/10.1056/NEJMoa1710895.

    Article  CAS  PubMed  Google Scholar 

  31. Gresser U, Gathof BS, Gross M. Benzbromarone and fenofibrate are lipid lowering and uricosuric: a possible key to metabolic syndrome? Adv Exp Med Biol. 1994;370:87–90.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from Science and Technology Commission of Shanghai Municipality (17411967000), and the National Natural Science Foundation of China (81301626 and 81671897). We sincerely acknowledge the help of all members of the Department of Nephrology and Rheumatology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine.

Author information

Authors and Affiliations

  1. Department of Nephrology and Rheumatology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, People’s Republic of China

    Haibo Yu, Xinying Liu, Yaxiang Song, Jiafen Cheng, Hui Bao, Ling Qin, Xuan Zhou, Ling Wang & Ai Peng

Authors
  1. Haibo Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xinying Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yaxiang Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jiafen Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hui Bao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ling Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Xuan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ling Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ai Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ling Wang or Ai Peng.

Ethics declarations

Ethical approval

This study (ClinicalTrials.gov, #NCT02338323) was conducted in Shanghai Tenth people’s hospital and under the Declaration of Helsinki and approved by the Medical Ethics Committee of Shanghai Tenth People’s Hospital of Tongji University (#SHSY-IEC-3.0/14–52/02).

Informed consent

Informed written consent was obtained from every patient before the enrollment. All data were analyzed anonymously.

Conflict of interest

The author declares that there is no competing interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, H., Liu, X., Song, Y. et al. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study. Clin Exp Nephrol 22, 1324–1330 (2018). https://doi.org/10.1007/s10157-018-1586-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-018-1586-y

Keywords

Search

Navigation